Health Check is renowned biotech journo Tim Boreham’s daily wrap covering morning movers and shakers of note in the ASX ...

A spokesperson for Advanz told pharmaphorum that, at the moment, the company does not have a timeline for when a ... Another potential option is Gilead Sciences PPAR agonist Livdelzi (seladelpar ...

GENEVA, 2 October 2024—Responding to today’s announcement by Gilead on lenacapavir ... HIV medicines at scale if the drugs are affordable and if there’s a clear timeline as to when the drugs will be ...

Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...

Gilead Sciences (GILD) ended the recent trading session at $85.83, demonstrating a +0.91% swing from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.76%.